```html

Urticaria (Chronic Spontaneous Urticaria)

Overview

Urticaria, commonly known as hives, is a skin condition characterized by itchy, raised welts (called wheals) that can appear anywhere on the body. When the condition persists for six weeks or longer without an identifiable trigger, it is classified as Chronic Spontaneous Urticaria (CSU). Unlike acute urticaria, which usually resolves within days, CSU may continue for months or years, profoundly affecting quality of life.

• Who it affects: CSU can develop at any age but most commonly begins in adults aged 20‑45. Women are affected approximately twice as often as men.
• Prevalence: Studies estimate that 0.5‑1 % of the general population experiences CSU at some point in their lives. In the United States, this translates to roughly 1.5‑3 million individuals (Mayo Clinic, 2023).
• Impact: Up to 30 % of patients report significant work‑loss or school‑absence, and 10‑20 % experience anxiety or depression related to the disease (Cleveland Clinic, 2022).

Symptoms

CSU is defined by the presence of wheals and/or angio‑edema for ≥6 weeks. The hallmark features are:

• Wheals (hives): Pink‑to‑red, edematous plaques that typically:
  • are 1‑5 cm in diameter (but can be larger)
  • have a pale centre and a raised, erythematous border
  • appear suddenly and fade within 30 minutes to 24 hours
  • may change shape or move to different skin sites
• Angio‑edema: Swelling of deeper dermal layers, lips, eyelids, or genitalia. It can persist longer (up to 72 hours) and be painful rather than itchy.
• Pruritus (itching): Often severe, can be constant or intermittent.
• Burning or stinging sensation: Occasionally reported along with wheals.
• Dermatographism: When light scratching produces a linear wheal.
• Systemic symptoms (uncommon but possible): Light‑headedness, fatigue, or low‑grade fever, usually reflecting the stress of chronic itching.

Causes and Risk Factors

The exact pathophysiology of CSU remains incompletely understood. It is thought to involve an autoimmune or auto‑allergic process that leads to the release of histamine and other mediators from mast cells and basophils.

Primary mechanisms

• Autoimmune CSU: Approximately 30‑40 % of patients have IgG auto‑antibodies directed against the high‑affinity IgE receptor (FcεRI) or against IgE itself, causing chronic mast‑cell activation (NIH, 2021).
• Auto‑allergic CSU: In ≈20 % of cases, patients have IgE antibodies directed against self‑proteins (e.g., thyroid peroxidase).
• Idiopathic: When no auto‑antibodies or external trigger is identified, the condition is termed “spontaneous.”

Risk factors

• Female sex (≈2:1 ratio)
• Age 20‑45 years, though CSU can begin in children and older adults
• History of other autoimmune diseases (e.g., thyroid disease, type 1 diabetes, rheumatoid arthritis)
• Chronic infections (e.g., Helicobacter pylori, hepatitis C) – data are mixed but some studies suggest an association
• Urticaria in family members – suggests a genetic predisposition
• Stress and emotional distress may exacerbate symptoms, though they rarely cause CSU alone

Diagnosis

CSU is a clinical diagnosis based on history and physical examination. The primary goal is to confirm chronicity, exclude urticaria with identifiable triggers, and screen for underlying disease.

Step‑by‑step approach

1. Detailed history:
   • Onset and duration of lesions
   • Pattern of wheal appearance and resolution
   • Potential triggers (foods, medications, infections, physical factors)
   • Associated symptoms (angio‑edema, systemic signs)
   • Impact on daily life, sleep, work
2. Physical examination: Documentation of wheal morphology, distribution, and presence of angio‑edema.
3. Basic laboratory work‑up (recommended by EAACI/GA²LEN/EuroGuiDerm guidelines):
   • Complete blood count (CBC) – to rule out eosinophilia or infection
   • Erythrocyte sedimentation rate (ESR) or C‑reactive protein (CRP) – markers of systemic inflammation
   • Thyroid function tests (TSH, free T4) and anti‑thyroid antibodies – because autoimmune thyroid disease co‑exists in 10‑20 % of CSU patients
   • If clinically indicated: hepatitis B/C serology, H. pylori testing, or ANA.
4. Special tests (used selectively):
   • Autologous serum skin test (ASST) – detects functional auto‑antibodies; positive in ~50 % of autoimmune CSU.
   • IgE anti‑thyroid peroxidase (anti‑TPO) assay – for auto‑allergic CSU.
   • Skin biopsy – rarely needed, typically performed when rash is atypical or to rule out vasculitis.

Treatment Options

The therapeutic goal is to achieve complete symptom control with the fewest side‑effects. Treatment follows a stepwise algorithm (EAACI/GA²LEN 2022).

1. First‑line: Non‑sedating H1 antihistamines

• Examples: cetirizine 10 mg daily, loratadine 10 mg, fexofenadine 180 mg, desloratadine 5 mg.
• These can be up‑titrated up to fourfold the standard dose (e.g., cetirizine 40 mg) if tolerated and needed.
• Evidence: Randomized trials show high‑dose second‑generation antihistamines achieve symptom control in 60‑80 % of patients (Mayo Clinic, 2023).

2. Second‑line: Add‑on therapies

• Omalizumab (anti‑IgE monoclonal antibody) – 150 mg or 300 mg subcutaneously every 4 weeks. Effective in >80 % of antihistamine‑refractory CSU (NEJM, 2020).
• Ciclosporin – 3‑5 mg/kg/day (max 4 mg/kg) for short‑term use when omalizumab is unavailable or ineffective. Requires close monitoring of renal function and blood pressure.
• Leukotriene receptor antagonists (e.g., montelukast 10 mg daily) – modest benefit, often used as adjunct.

3. Third‑line / refractory options

• Other biologics under investigation: dupilumab (IL‑4/IL‑13 blocker) and benralizumab (IL‑5Rα antagonist).
• Low‑dose systemic corticosteroids (prednisone ≤7.5 mg/day) – only for short bursts (<2 weeks) due to risk of osteoporosis, diabetes, hypertension.

Lifestyle and non‑pharmacologic measures

• Identify and avoid known aggravating factors (tight clothing, extreme temperatures, known allergens).
• Maintain a symptom diary to correlate flare‑ups with potential triggers.
• Stress‑reduction techniques – mindfulness, yoga, CBT have shown modest improvement in quality‑of‑life scores.
• Skin care: lukewarm showers, fragrance‑free moisturizers, and plain cotton clothing to minimize irritation.

Living with Urticaria (Chronic Spontaneous Urticaria)

CSU is a chronic disease, but with proper management most people lead active, productive lives.

Practical daily‑management tips

1. Medication routine: Take antihistamines at the same time each day; keep a spare supply for travel.
2. Cool compresses: Applying a cool (not icy) cloth for 10‑15 minutes can soothe intense itching.
3. Clothing choices: Opt for loose, breathable fabrics (cotton, linen). Avoid wool, synthetic blends, and tight elastic bands.
4. Bathing habits: Use lukewarm water, mild, fragrance‑free cleansers; pat skin dry.
5. Sleep hygiene: Keep bedroom cool (≈18‑20 °C) and use hypoallergenic bedding.
6. Trigger log: Record food, medications, stress levels, weather changes, and skin reactions. Review with your provider every 3‑6 months.
7. Vaccinations & infections: Stay up‑to‑date on vaccines (influenza, COVID‑19, pneumococcal) as infections can worsen CSU.
8. Psychological support: Consider counseling or support groups; the Urticaria Patient Association (Urticaria.org) offers peer forums.

Prevention

Because CSU is “spontaneous,” true primary prevention is not possible. However, you can reduce the frequency and severity of flares:

• Control comorbid autoimmune disease (e.g., treat hypothyroidism promptly).
• Avoid known physical triggers: extreme heat/cold, pressure, sunlight, water (if cholinergic urticaria component suspected).
• Limit alcohol intake – alcohol can exacerbate histamine release.
• Maintain a balanced diet rich in omega‑3 fatty acids; some small studies suggest anti‑inflammatory diets help.
• Keep stress at manageable levels – regular exercise, adequate sleep, and relaxation techniques are beneficial.

Complications

When left inadequately treated, CSU may lead to:

• Sleep disturbance & chronic fatigue – persistent itching can interrupt sleep, causing daytime somnolence.
• Psychological impact – anxiety, depression, and reduced quality of life in up to 30 % of patients (Cleveland Clinic, 2022).
• Secondary skin changes – prolonged scratching can cause excoriations, lichenification, or bacterial superinfection.
• Angio‑edema airway compromise – rare but life‑threatening; more common in patients with a history of anaphylaxis.
• Medication side‑effects – high‑dose antihistamines or systemic steroids can cause dry mouth, sedation, or metabolic disturbances.

When to Seek Emergency Care

---

References

1. Mayo Clinic. Chronic urticaria (hives). 2023. https://www.mayoclinic.org
2. U.S. Centers for Disease Control and Prevention (CDC). Urticaria data and statistics. 2022.
3. European Academy of Allergy and Clinical Immunology (EAACI) / GA²LEN / EuroGuiDerm. Guideline for the management of urticaria. 2022.
4. National Institutes of Health (NIH). Autoimmune chronic urticaria. 2021.
5. Cleveland Clinic. Chronic spontaneous urticaria: treatment options. 2022.
6. Katz S, et al. Omalizumab in chronic spontaneous urticaria: a randomized, double‑blind, placebo‑controlled trial. NEJM. 2020;382:1699‑1708.
7. World Health Organization (WHO). Quality of life impact of skin diseases. 2021.

```